OWKIN Revenue and Competitors

Claim your profile

Location

#368

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • OWKIN's estimated annual revenue is currently $49.6M per year.(i)
  • OWKIN received $Undisclosed in venture funding in March 2019.
  • OWKIN's estimated revenue per employee is $193,750
  • OWKIN's total funding is $254.1M.
  • OWKIN's current valuation is $1B. (November 2021)

Employee Data

  • OWKIN has 256 Employees.(i)
  • OWKIN grew their employee count by 43% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.1M3343%N/AN/A
#2
$32.9M212-10%N/AN/A
#3
$0.5M6-14%$10MN/A
#4
$7.5M3911%$51.6MN/A
#5
$4.3M31-9%$3.3MN/A
#6
$6M3922%N/AN/A
#7
$4.2M27-16%N/AN/A
#8
$0.7M9-18%$3.2MN/A
#9
$57M3684%N/AN/A
#10
$115.6M9941%$61MN/A

OWKIN was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology and Gilles Wainrib, PhD, a pioneer in the field of Artificial Intelligence in biology. OWKIN is an AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes. Our team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters (top global 100), a DREAM Challenge top performer, and publications in ICML, NIPS and other top scientific journals. OWKIN develops scientific collaborations with top-tier medical institutions such as Mount Sinai, Inserm, Institut Curie and the Léon Bérard Center, and partners with leading pharmaceutical companies, including Amgen, Roche, and Ipsen. OWKIN has developed a state-of-the-art federated learning technology in healthcare to overcome the data sharing problem, building collective intelligence from distributed data at scale while preserving data privacy and security.

keywords:Biotechnology, Pharmaceuticals, Big Data, Artificial Intelligence

$254.1M

Total Funding

256

Number of Employees

$49.6M

Revenue (est)

43%

Employee Growth %

$1B

Valuation

N/A

Accelerator

OWKIN News

2022-04-17 - Feast table at En’owkin Centre in Penticton creates community

The En'owkin Centre is a place where cultural teachers come together to revive language, culture and also the arts.

2022-04-13 - En'owkin Centre unveils the Four Food Chiefs Feast Table in ...

En'owkin Culture, Arts & Higher Learning Program commissioned artist Cody Lecoy to design and paint the surface of the table. The En'owkin...

2021-11-22 - Owkin secures $180M Series B

Pharma giant Sanofi has made an equity investment worth $180 million in French-American startup Owkin, an AI and precision medicine company. The round includes $90 million over the next three years, plus additional payments based on research milestones. The companies will collaborate on treatmen ...

2021-11-19 - AI-based biotech startup Owkin becomes France’s new ‘unicorn’ after raising €159M from Sanofi

French and US-based Owkin, a startup that provides machine learning to allow medical researchers to test AI models on distributed data, has raised $180M (approx €159M) in a fresh round of funding. With a valuation of more than $1B, Owkin has now earned the status of a ‘unicorn’. The investment ...

2021-11-18 - OWKIN, INC. announced that it has received $180 million in funding from Sanofi

OWKIN, INC. announced that it has received $180,000,000 in a round of funding on November 18, 2021. The transaction included participation from new investor Sanofi. The round is raised at a post-money valuation of $1,000,000,000.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$62M25632%N/A
#2
$80.3M25644%$156.7M
#3
$35.8M256156%$249.8M
#4
$38.5M25619%$223.1M
#5
$42.2M256N/AN/A

OWKIN Funding

DateAmountRoundLead InvestorsReference
2018-01-17$11.0MAOtium VentureArticle
2018-05-24$UndisclosedAGVArticle
2019-03-08$UndisclosedUndisclosedF-Prime CapitalArticle